Brief: Ultimovacs Announces NIPU Results Presented At ESMO 2023

Zelluna ASA

17/10/2023 17:05

Oct 17 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * REG-ULTIMOVACS ANNOUNCES NIPU RESULTS PRESENTED AT ESMO
2023:
SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL
SURVIVAL FOR PATIENTS RECEIVING UV1 CANCER VACCINE IN PHASE II
NIPU TRIAL IN MALIGNANT MESOTHELIOMA
    * NO ADDITIONAL SAFETY CONCERNS WERE REPORTED FROM UV1
TREATMENT.

Source text for Eikon:  ID:nGNE61DZ5D 
Further company coverage:  ULTI.OL 

 ((Reuters.Briefs@thomsonreuters.com;))